Revefenacin Area Under the Curve Spirometry in Patients with Moderate to Very Severe COPD.

Autor: LeMaster WB; Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN, USA., Witenko CJ; Theravance Biopharma US, Inc, South San Francisco, CA, USA., Lacy MK; Theravance Biopharma US, Inc, South San Francisco, CA, USA., Olmsted AW; Theravance Biopharma US, Inc, South San Francisco, CA, USA., Moran EJ; Theravance Biopharma US, Inc, South San Francisco, CA, USA., Mahler DA; Geisel School of Medicine at Dartmouth, Hanover, NH, USA.; Respiratory Services, Valley Regional Hospital, Claremont, NH, USA.
Jazyk: angličtina
Zdroj: International journal of chronic obstructive pulmonary disease [Int J Chron Obstruct Pulmon Dis] 2024 Oct 16; Vol. 19, pp. 2299-2308. Date of Electronic Publication: 2024 Oct 16 (Print Publication: 2024).
DOI: 10.2147/COPD.S483176
Abstrakt: Purpose: Several lung function endpoints are utilized in clinical trials of inhaled bronchodilators for chronic obstructive pulmonary disease (COPD). Trough forced expiratory volume in 1 second (FEV 1 ) is a commonly reported endpoint in COPD trials and can be complemented by area under the FEV 1 vs time curve (FEV 1 AUC), which provides information on duration and consistency of bronchodilation over a dosing interval. Revefenacin, a once-daily bronchodilator, significantly improved lung function in patients with COPD when measured by trough FEV 1 in two replicate Phase 3 trials. Here, we report an FEV 1 AUC substudy using data from these trials.
Patients and Methods: This post hoc analysis examined substudy data from 12-week replicate Phase 3 trials (NCT02459080/NCT02512510); patients with moderate to very severe COPD were randomized 1:1 to revefenacin 175 μg or placebo once daily. The substudy patients had FEV 1 AUC 0-2h assessed on Day 1, and those who continued to Day 84 also underwent 24-hour serial spirometry postdose where FEV 1 AUC 0-2h, AUC 0-12h , AUC 12-24h , and AUC 0-24h were evaluated.
Results: Fifty and 47 patients who received revefenacin and placebo underwent 24-hour serial spirometry; most baseline characteristics were aligned between groups. At Day 84 postdose, revefenacin demonstrated sustained improvements in bronchodilation over 24 hours; differences in least squares mean vs placebo were 282, 220, 205, and 212 mL for FEV 1 AUC 0-2h , AUC 0-12h , AUC 12-24h , and AUC 0-24h (all P <0.001), respectively.
Conclusion: This substudy analysis supplements previous findings that revefenacin provides sustained bronchodilation over 24 hours. Assessing additional complementary COPD clinical trial endpoints can help clinicians make treatment decisions.
Competing Interests: Corey J. Witenko is a current employee of Theravance Biopharma US, Inc. and owns stock. Melinda K. Lacy is a current employee of Theravance Biopharma US, Inc. and owns stock. Ann W. Olmsted is a paid consultant for Theravance Biopharma US, Inc. and owns stock. Edmund J. Moran is a current employee of Theravance Biopharma US, Inc. and owns stock. In addition, Edmund J. Moran has a patent US11484531 licensed to Viatris. Donald A. Mahler serves on the advisory boards of AstraZeneca, Boehringer Ingelheim, Theravance, Verona, and Viatris and receives royalties from pharmaceutical companies (Elpen Pharmaceutical Company and University of Aberdeen) for the use of baseline dyspnea index/transition dyspnea index. The authors report no other conflicts of interest in this work.
(© 2024 LeMaster et al.)
Databáze: MEDLINE
Externí odkaz: